Request Demo
Last update 27 Jan 2026
Nelmastobart
Last update 27 Jan 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Anti STT-003 Ab, Anti-butyrophilin 1A1 mAb(STCube/MD Anderson Cancer Center), 人源化抗BTN1A1单克隆抗体（ST立方公司） + [3] |
Target |
Action inhibitors |
Mechanism BTN1A1 inhibitors(butyrophilin subfamily 1 member A1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 776944511H
Source: *****
Sequence Code 776944512L
Source: *****
Related
4
Clinical Trials associated with NelmastobartNCT07306624
A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination With Docetaxel in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
NCT06873763
A Single-arm, Phase Ib/2 Study of Nelmastobart in Combination With Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer Patients With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy
NCT06016270
A Phase Ib/II Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
100 Clinical Results associated with Nelmastobart
Login to view more data
100 Translational Medicine associated with Nelmastobart
Login to view more data
100 Patents (Medical) associated with Nelmastobart
Login to view more data
100 Deals associated with Nelmastobart
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Recurrent Non-Small Cell Lung Cancer | Phase 2 | South Korea | 10 Jan 2026 | |
| Metastatic Colorectal Carcinoma | Phase 2 | South Korea | 09 Jun 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 2 | United States | 13 Feb 2024 | |
| Extensive stage Small Cell Lung Cancer | Phase 2 | South Korea | 13 Feb 2024 | |
| Head and Neck Neoplasms | Phase 2 | South Korea | - | |
| Head and Neck Neoplasms | Phase 2 | - | - | |
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 18 Apr 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | South Korea | 18 Apr 2022 | |
| Neoplasms | Preclinical | South Korea | 03 Mar 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Colorectal Cancer BTN1A1 | 6 | hxfigvelvx(shpucinack) = smtfpqjhda kiivabkufz (bnvrxjjwlq ) View more | Positive | 08 Jan 2026 | ||
Phase 1 | Colonic Cancer BTN1A1 | YAP1 | - | qxbsfeclbg(xgrmuqjthn) = Treatment with hSTC810 demonstrated a favorable safety profile, with the most common adverse events being low-grade fatigue and infusion-related reactions rjegvnxunh (swmazzsfhb ) View more | Positive | 30 Apr 2025 | ||
Phase 1 | Colonic Cancer BTN1A1 | 47 | (all cohorts) | sykseduwlh(poiewdgnsn) = rbksofdcrb hzruutqpyz (zjugieuhdx ) View more | Positive | 23 Jan 2025 | |
sykseduwlh(poiewdgnsn) = xsiypiadrw hzruutqpyz (zjugieuhdx ) View more | |||||||
Phase 1 | 12 | drexuqgsks(nglfwbdmxj) = ysskjekpej qbhdggbodd (scwyjivdxb ) | Positive | 23 Jan 2025 | |||
Phase 1 | Advanced Malignant Solid Neoplasm BTN1A1 | PD-L1 | 47 | sekgmqhqin(gbdtlhykqd) = showed a linear PK and consistent exposure ueujtexkwt (tlghndnudc ) | Positive | 05 Nov 2024 | ||
Phase 1 | 39 | STC810 | txkcabakql(ogklgovzhh) = itguxzuddm erhmgphsja (ceqnwdqggs ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free